Infinity’s IPI-145 Shoots From Phase I To Pivotal CLL Study
Enrollment begins in Phase III study of IPI-145 in relapsed/refractory CLL, after releasing Phase I results at ASH that the company believes prove the drug is differentiated from other PI3 kinase inhibitors by potency.
You may also be interested in...
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.
Patients with the most severe type of disease were all randomized to treatment with the study drug, which may have had a negative impact on outcome, the Israeli company suggested.